Patient Safety Movement Foundation Calls for Action in Advance of Second Annual #UniteForSafeCare Event
31.8.2021 15:00:00 EEST | Business Wire | Press release
The second annual #UniteForSafeCare event is scheduled for Friday, September 17th in conjunction with World Patient Safety Day. The event is hosted by the Patient Safety Movement Foundation (PSMF) and co-convened with The Leapfrog Group to bring global awareness to the lack of safety in healthcare and the fact that more than three million people die each year as the result of unsafe care. The event will explore how the public and other stakeholders can call for high reliability in healthcare, as well as the World Health Organization’s 2021 theme of “safe maternal and newborn care.”
As part of this year’s event, leadership from the Patient Safety Movement Foundation will coordinate demonstrations on both the east and west coasts in honor of World Patient Safety Day. Patient Safety Movement Foundation CEO Dr. David B. Mayer will continue his walk which began in February 2020 to raise awareness of patient and healthcare worker safety. Since starting, he has covered over 3,400 miles and been joined by families impacted by patient harm in over 30 states. This year’s walk will begin on September 11th on the 20th anniversary of the terrorist attacks to honor the lives lost and impacted, and will start in Gettysburg, Penn. Gettysburg was chosen as the starting point due to its strong visual representation of lives lost during the American Civil War drawing parallel to the lives lost each day due to unsafe care. The walk will finish in front of the White House in a call for action before continuing on to Capitol Hill.
“Over 8,220 people die every day in hospitals worldwide from unsafe care – that’s six people every minute – and the pandemic is making the delivery of safe care even harder,” stated Mayer. “This annual event allows us to bring the community and stakeholders together to raise awareness of this issue and advocate for change to make zero preventable deaths a reality.”
Here are the ways you can get involved this year:
- Attend the free virtual event: The virtual event will occur from 11 a.m. to 3:15 p.m. PDT on Friday, September 17th. At the event, attendees will have the chance to hear from Patient Safety Movement Foundation leadership, as well as over 20 speakers including Tedros Adhanom Ghebreyesus, PhD, MSc, director-general of the World Health Organization. Dariush Eghbali, an Iranian artist and humanitarian, will be performing and attendees will have the opportunity to network and access exhibitor booths. In addition, there will be a panel with the showrunner and cast of Peacock’s TV series “Dr. Death” followed by a segment to memorialize the patients we’ve lost due to preventable harm. Attendees will have the opportunity to bid on items up for auction – including a private screening and Q&A session with the filmmaker of HBO’s “Bleed Out,” as well as a conversation with Patrick Macmanus, the showrunner of “Dr. Death.” All proceeds of the auction support awareness and education initiatives. To see the full schedule and RSVP, visit: https://patient.sm/B15-UFSC.
- Host your own walk: Download the Charity Miles app and walk on your own or invite your coworkers and community to dedicate a walk, run, bike or any movement to show your support for the cause.
- Make a donation : Donations help fund awareness and education campaigns throughout the year. Individuals can make donations in honor of loved ones who have been affected by preventable medical harm. PSMF will plant an orange flag in Orange County or Washington D.C. for any donation of $10 or more. To help PSMF reach its goal of $250,000, visit: https://patient.sm/PR-UFSC-Donate.
- Share on social: Spread the word and help advocate for safer care by increasing awareness on social media. Use the hashtag #uniteforsafecare or translate it into any language to keep the conversation going globally.
- Send in your art: New this year, a virtual patient, family and survivor art gallery is available for individuals to share personal expressions of the emotions they felt as they navigated experiences with medical errors – whether it ended in tragedy or in joy. The art will be displayed along with a place to share the meaning behind the piece. To view the art or submit your own piece, visit: https://patient.sm/B15-Artwork.
- Wear and “light up” orange: Show your support by wearing orange, the official World Patient Safety Day color, or lighting up your house, a local monument or business orange. Share your photos on social media between September 13th and September 17th. You can also purchase official campaign t-shirts and hats: https://patient.sm/B15-Shop.
This year’s event is made possible by the generous sponsorship of Dr. Steven J. Barker, Gordon & Betty Moore Foundation, HealthySimulation.com, Jewish Healthcare Foundation, Josie King Foundation, Kaiser Permanente, Liamar Healthcare, Medstar Health Institute for Quality and Safety and Teletracking. To learn more about #UniteForSafeCare, visit: https://patientsafetymovement.org/unite-for-safe-care/home/.
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005375/en/
Contact information
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
